自然周期与人工周期冻融胚胎移植后的产科和新生儿结局及黄体期支持的作用:系统综述与Meta分析
本系统综述与Meta分析纳入30项观察性研究(自然周期冻融胚胎移植n=56445,人工周期n=57231),比较单胎妊娠的产科和新生儿结局。自然周期冻融胚胎移植较人工周期降低大于胎龄儿、巨大儿、低出生体重、早期妊娠丢失、早产、极早产、妊娠期高血压疾病、子痫前期、前置胎盘和产后出血的风险,但出生体重较低。在自然周期冻融胚胎移植中使用黄体期支持可能降低早产风险,但证据质量极低,无法就黄体期支持的使用给出推荐。
要点
- 自然周期冻融胚胎移植较人工周期降低多种不良产科和新生儿结局风险。
- 自然周期冻融胚胎移植后出生体重较人工周期低26.35克(95%CI 11.61-41.08)。
- 黄体期支持对多数结局无修饰作用,早产风险降低的证据质量极低。
核心结论
- 自然周期冻融胚胎移植较人工周期降低不良产科和新生儿结局风险,估计每1000名妇女可预防4至22例不良结局。
- 自然周期冻融胚胎移植应作为有排卵周期妇女冻融胚胎移植的首选治疗。
- 基于极低质量证据,自然周期冻融胚胎移植中使用黄体期支持可能降低早产风险,但无法就黄体期支持的使用给出推荐。
研究设计与样本
- 系统综述与Meta分析,检索CINAHL、EMBASE和MEDLINE从建库至2022年10月10日。
- 纳入30项观察性研究(包括队列研究和登记研究),自然周期冻融胚胎移植n=56445,人工周期n=57231,其中19项研究在自然周期中使用黄体期支持。
- 使用ROBINS-I工具评估偏倚风险,采用GRADE方法评价证据质量,使用随机效应模型计算合并OR、RD、调整OR和患病率估计及95%CI,异质性用I²评估。
主要发现
- 自然周期冻融胚胎移植较人工周期出生体重较低(均数差26.35克;95%CI 11.61-41.08,I²=63%)。
- 自然周期冻融胚胎移植较人工周期降低大于胎龄儿(OR 0.88,95%CI 0.83-0.94,I²=54%)、巨大儿(OR 0.81,95%CI 0.71-0.93,I²=68%)、低出生体重(OR 0.81,95%CI 0.77-0.85,I²=41%)、早期妊娠丢失(OR 0.73,95%CI 0.61-0.86,I²=70%)、早产(OR 0.80,95%CI 0.75-0.85,I²=20%)、极早产(OR 0.66,95%CI 0.53-0.84,I²=0%)、妊娠期高血压疾病(OR 0.60,95%CI 0.50-0.65,I²=61%)、子痫前期(OR 0.50,95%CI 0.42-0.60,I²=44%)、前置胎盘(OR 0.84,95%CI 0.73-0.97,I²=0%)和产后出血(OR 0.43,95%CI 0.38-0.48,I²=53%)的风险。
- 分层分析提示,与人工周期相比,自然周期冻融胚胎移植联合黄体期支持降低早产风险(OR 0.75,95%CI 0.70-0.81),而不联合黄体期支持未降低早产风险;黄体期支持未修饰其他结局。
- 异质性从低到高不等,证据质量从极低到中等。
关键数值与推荐
- 自然周期冻融胚胎移植较人工周期出生体重均数差26.35克(95%CI 11.61-41.08,I²=63%)。
- 自然周期冻融胚胎移植较人工周期大于胎龄儿OR 0.88(95%CI 0.83-0.94,I²=54%)。
- 自然周期冻融胚胎移植较人工周期巨大儿OR 0.81(95%CI 0.71-0.93,I²=68%)。
- 自然周期冻融胚胎移植较人工周期低出生体重OR 0.81(95%CI 0.77-0.85,I²=41%)。
- 自然周期冻融胚胎移植较人工周期早期妊娠丢失OR 0.73(95%CI 0.61-0.86,I²=70%)。
临床怎么用
- 自然周期冻融胚胎移植应作为有排卵周期妇女冻融胚胎移植的首选治疗。
- 基于极低质量证据,自然周期冻融胚胎移植中使用黄体期支持可能降低早产风险,但无法就黄体期支持的使用给出推荐。
- 未来需要研究黄体期支持的有效性和安全性。
局限性
- 异质性从低到高不等(如出生体重I²=63%,巨大儿I²=68%,早期妊娠丢失I²=70%)。
- 证据质量从极低到中等。
- 关于黄体期支持有效性的争议存在许多不确定性,未来需要研究黄体期支持的有效性和安全性。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The number of frozen embryo transfers (FET) has increased dramatically over the past decade. Based on current evidence, there is no difference in pregnancy rates when natural cycle FET (NC-FET) is compared to artificial cycle FET (AC-FET) in subfertile women. However, NC-FET seems to be associated with lower risk of adverse obstetric and neonatal outcomes compared with AC-FET cycles. Currently, there is no consensus about whether NC-FET needs to be combined with luteal phase support (LPS) or not. The question of how to prepare the endometrium for FET has now gained even more importance and taken the dimension of safety into account as it should not simply be reduced to the basic question of effectiveness. OBJECTIVE AND RATIONALE: The objective of this project was to determine whether NC-FET, with or without LPS, decreases the risk of adverse obstetric and neonatal outcomes compared with AC-FET. SEARCH METHODS: A systematic review and meta-analysis was carried out. A literature search was performed using the following databases: CINAHL, EMBASE, and MEDLINE from inception to 10 October 2022. Observational studies, including cohort studies, and registries comparing obstetric and neonatal outcomes between singleton pregnancies after NC-FET and those after AC-FET were sought. Risk of bias was assessed using the ROBINS-I tool. The quality of evidence was evaluated using the Grading of Recommendations Assessment, Development and Evaluation approach. We calculated pooled odds ratios (ORs), pooled risk differences (RDs), pooled adjusted ORs, and prevalence estimates with 95% CI using a random effect model, while heterogeneity was assessed by the I2. OUTCOMES: The conducted search identified 2436 studies, 890 duplicates were removed and 1546 studies were screened. Thirty studies (NC-FET n = 56 445; AC-FET n = 57 231) were included, 19 of which used LPS in NC-FET. Birthweight was lower following NC-FET versus AC-FET (mean difference 26.35 g; 95% CI 11.61-41.08, I2 = 63%). Furthermore NC-FET compared to AC-FET resulted in a lower risk of large for gestational age (OR 0.88, 95% 0.83-0.94, I2 = 54%), macrosomia (OR 0.81; 95% CI 0.71-0.93, I2 = 68%), low birthweight (OR 0.81, 95% CI 0.77-0.85, I2 = 41%), early pregnancy loss (OR 0.73; 95% CI 0.61-0.86, I2 = 70%), preterm birth (OR 0.80; 95% CI 0.75-0.85, I2 = 20%), very preterm birth (OR 0.66, 95% CI 0.53-0.84, I2 = 0%), hypertensive disorders of pregnancy (OR 0.60, 95% CI 0.50-0.65, I2 = 61%), pre-eclampsia (OR 0.50; 95% CI 0.42-0.60, I2 = 44%), placenta previa (OR 0.84, 95% CI 0.73-0.97, I2 = 0%), and postpartum hemorrhage (OR 0.43; 95% CI 0.38-0.48, I2 = 53%). Stratified analyses on LPS use in NC-FET suggested that, compared to AC-FET, NC-FET with LPS decreased preterm birth risk, while NC-FET without LPS did not (OR 0.75, 95% CI 0.70-0.81). LPS use did not modify the other outcomes. Heterogeneity varied from low to high, while quality of the evidence was very low to moderate. WIDER IMPLICATIONS: This study confirms that NC-FET decreases the risk of adverse obstetric and neonatal outcomes compared with AC-FET. We estimate that for each adverse outcome, use of NC-FET may prevent 4 to 22 cases per 1000 women. Consequently, NC-FET should be the preferred treatment in women with ovulatory cycles undergoing FET. Based on very low quality of evidence, the risk of preterm birth be decreased when LPS is used in NC-FET compared to AC-FET. However, because of many uncertainties-the major being the debate about efficacy of the use of LPS-future research is needed on efficacy and safety of LPS and no recommendation can be made about the use of LPS.
引用
- Zaat TR, Kostova EB, Korsen P, et al. Obstetric and neonatal outcomes after natural versus artificial cycle frozen embryo transfer and the role of luteal phase support: a systematic review and meta-analysis. Hum Reprod Update. 2023. PMID: 37172270. doi:10.1093/humupd/dmad011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。